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Abstract
Introduction: Conflicting findings in both interventional and observational studies have resulted in a lack of
consensus on the benefits of ω3 fatty acids in reducing disease risk. This may be due to individual variability in
response. We used a multi-platform lipidomic approach to investigate both the consistent and inconsistent responses
of individuals comprehensively to a defined ω3 intervention.
Methods: The lipidomic profile including fatty acids, lipid classes, lipoprotein distribution, and oxylipins was examined
multi- and uni-variately in 12 healthy subjects pre vs. post six weeks of ω3 fatty acids (1.9 g/d eicosapentaenoic acid
[EPA] and 1.5 g/d docosahexaenoic acid [DHA]).
Results: Total lipidomic and oxylipin profiles were significantly different pre vs. post treatment across all subjects
(p=0.00007 and p=0.00002 respectively). There was a strong correlation between oxylipin profiles and EPA and DHA
incorporated into different lipid classes (r2=0.93). However, strikingly divergent responses among individuals were
also observed. Both ω3 and ω6 fatty acid metabolites displayed a large degree of variation among the subjects. For
example, in half of the subjects, two arachidonic acid cyclooxygenase products, prostaglandin E2 (PGE2) and
thromboxane B2 (TXB2), and a lipoxygenase product, 12-hydroxyeicosatetraenoic acid (12-HETE) significantly
decreased post intervention, whereas in the other half they either did not change or increased. The EPA
lipoxygenase metabolite 12-hydroxyeicosapentaenoic acid (12-HEPE) varied among subjects from an 82% decrease
to a 5,000% increase.
Conclusions: Our results show that certain defined responses to ω3 fatty acid intervention were consistent across
all subjects. However, there was also a high degree of inter-individual variability in certain aspects of lipid
metabolism. This lipidomic based phenotyping approach demonstrated that individual responsiveness to ω3 fatty
acids is highly variable and measurable, and could be used as a means to assess the effectiveness of ω3
interventions in modifying disease risk and determining metabolic phenotype.
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Introduction
The widely reported beneficial effects of ω3 fatty acids (FA)
in modifying risk for chronic diseases, particularly heart
disease, have recently been called into question. A recent
meta-analysis of 20 randomized clinical trials including over
68,000 patients reported no statistically significant effect of ω3
fatty acids either taken as supplements or through diet (largely
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as fatty fish) on all-cause mortality, cardiac death, sudden
death, myocardial infarction or stroke [1]. This result has come
as a surprise after several decades of reports of beneficial
effects, starting with the early studies in the 1970s that found
low rates of heart disease in Inuit populations with high ω3
diets [2]. Conflicting reports arose as early as 9 years ago,
when the DART-2 trial, discovered an apparent harmful effect
of ω3 taken as fish oil supplements [3]. Subsequently, several
insightful reviews and commentaries have highlighted the need
to personalize dietary interventions such as ω3 fatty acid intake
to individual needs and to consider the broader context of the
overall diet and environment [4,5]. The question remains, if it is
indeed true that different groups of individuals respond
differently to ω3 FA, can these differences in response be
measured and quantified in order to enable a more
personalized approach?
There is evidence that combined intakes of 250-500 mg/d of
eicosapentaenoic acid (EPA; 20:5n3) and docosahexaenoic
acid (DHA; 22:6n3), the two main long-chain ω3 FA that are
associated with most of the bioactivity of ω3s, significantly
reduce the risk of fatal coronary heart disease, primarily
through the prevention of cardiac arrhythmias [6]. Other
potential mechanisms by which ω3 FA may be reducing heart
disease risk include lowering plasma triglycerides [7], modifying
lipoprotein particle size, decreasing blood pressure, as well as
inhibiting platelet aggregation [8]. It is universally agreed that
ω3 FA decrease the production of VLDL, thereby reducing
plasma triglycerides by as much as 30-50% [9]. The effects on
lipoprotein particle distribution, including a decrease in VLDL
size, increases in LDL and HDL size, and increases or
decreases in LDL and HDL cholesterol are inconsistent and
may be due to differences in the specific effects of the
individual long chain ω3 EPA and DHA [10-12] as well as
genetic factors [13], however, the variability in these responses
has not been well characterized to date. Additionally, ω3 FA
have been implicated in decreasing inflammation via direct
effects on lipid signaling mediators, or oxylipins. ω3 FA
decrease production of several pro-inflammatory ω6
arachidonic acid (ARA, 20:4n6) derived eicosanoids including
the cyclooxygenase (COX) product prostaglandin E2 (PGE2)
[14] and the lipoxygenase (LOX) product leukotriene B4 (LTB4)
both in vivo and in vitro [14-18]. The doses of EPA and DHA
that are associated with all of the above effects (decreasing
triglycerides, modifying lipoprotein particle distribution, and
anti-inflammatory effects) are typically much higher than the
250-500 mg/d dose needed for anti-arrhythmia effects and are
in the range of 1-5 g/d EPA+DHA.
We hypothesized that a comprehensive lipidomic approach
is necessary to determine the overall effects of ω3 fatty acids in
individuals. We further hypothesized that a comprehensive
lipidomic approach for measuring response to ω3 fatty acids
would reveal both those aspects of response that are
consistent and those that vary among individuals. Recently, the
effects of ω3 FA on partial plasma lipidomes have been
published, including a report on fatty acids and lipid classes
[19], studies on oxylipins in healthy subjects [20], in patients
with IgA nephropathy [21], and in patients with asthma [22],
and a number of publications on the effects on lipoproteins
(reviewed in 11,23-26). However, the effects on the
comprehensive lipidomic profile including fatty acids, lipid
classes, lipoprotein distribution, and oxylipins have not been
examined simultaneously to date. In this study, we examined
the comprehensive lipidomic profiles in 12 healthy subjects pre
vs. post 6 weeks of administration of ω3 FA taken as fish oil
delivering 1.9 g/d EPA + 1.5 g/d DHA.
Methods
Subjects
This was an open label, single arm intervention pilot study
completed during the summer of 2008 to investigate the ability
of comprehensive lipid profiling to discern both the variable and
consistent aspects of lipid metabolic responsiveness to ω3 FA
in healthy subjects. Healthy subjects were recruited on the
University of California Davis campus by flyering and
announcements at seminars. They were healthy adults with the
following mean (± SD) characteristics: age, 32 ± 8 y; weight, 67
± 17 kg; body mass index (BMI), 23 ± 3 kg/m2. Exclusion
criteria were age < 18 or > 65, pregnancy or nursing, any
existing medical condition/disease diagnosis, BMI < 18 or > 30,
anemia and/or conditions that would influence ability to donate
blood safely, and recently recovering from an illness, injury, or
infection. The subjects ate their regular diets throughout the
study except they abstained from eating seafood or
supplements containing ω3 FA. The subjects were
administered 6 g/d fish oil (Ocean Nutrition, lot 18394)
containing ω3 FA (1.9 g/d EPA + 1.5 g/d DHA) in capsule form,
representing 32% and 25% of FA, as provided in the certificate
of analysis. The FA composition of the fish oil capsules (data
provided by manufacturer) was as follows: 35% 20:5n3, 26%
22:6n3, 2% 18:1n9, 11% 20:1n9, 2% 20:4n6, 2% 20:4n3, 6%
22:1n11, 1% 22:1n9, 1% 21:5n3, 6% 22:5n3, 1% 24:1n9, and
about 6% of other minor FA each at less than 1%
concentration.
The subjects came to the Ragle Center on the University of
California campus on three occasions. On the first visit, study
personnel screened and consented the subjects. Subjects filled
out a questionnaire about their health and current medication
use to determine whether they met inclusion criteria (weight at
least 49 kg, adult (aged 18-65 years old), disclose which
medications currently taking, able to come to the Ragle Center
at the designated time, able to give blood, able to take 6 g fish
oil per day for 6 weeks, able to carry out first morning urine
collection, able to stop or avoid taking NSAIDs and allergy
medications for 6 weeks, able to stop or avoid eating seafood
and seaweed for 6 weeks). At the baseline and post-
intervention visits fasting blood samples were collected by
venipuncture after a 12-hour overnight fast and height and
weight were recorded. Blood was collected using BD
Vacutainer lavender-top EDTA tubes. Whole blood was
centrifuged in a tabletop ultracentrifuge for 10 min at 4°C at
13,000 rpm within 15 min of collection. The plasma was
separated into 1.5-mL aliquots and immediately frozen at -70°C
until analysis. Subjects also collected first morning urine
samples however urine analysis results are not reported here.
Lipidomics of Response to Omega-3 Fatty Acids
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Study personnel administered 6 weeks of fish oil capsules
(each week’s supply of capsules in an individual bottle) at the
baseline visit. Subjects were instructed to take 6 capsules each
day at their convenience at home/work, with a suggestion to
take the capsules at the same time each day, preferably in the
evening after the last meal of the day. After 6 weeks the
subjects returned for the post intervention visit at which time
another fasting blood draw was collected and subjects’ weight
and height was measured. Subjects kept 3-day diet records at
the beginning and end of the study. Subjects were
compensated for their time with gift cards and were also given
their baseline blood lipid results. Study personnel contacted
subjects by e-mail and/or phone throughout the 6 weeks of the
study to ensure compliance and to remind subjects about their
post-intervention visit. Twenty-three subjects were screened for
eligibility, 6 of whom were taking medications and/or were not
willing to abstain from taking medications, and 4 of whom
declined to be enrolled. Thirteen subjects were enrolled with
one subject dropping out due to gastrointestinal discomfort
(diarrhea) after the first day of the study. Twelve subjects (8
female, 4 male) completed the study and were included in the
analysis. Two of the female subjects reported that their
menstrual cycles were significantly longer than usual during the
course of the intervention but there were no reports of adverse
events and the fish oil was well tolerated. The subject
characteristics are summarized in Table 1. Sample size
calculations were not possible given the exploratory nature of
the study.
Ethics Statement.  The Institutional Review Board of the
University of California Davis approved the study protocol, and
written informed consent was obtained from all subjects. The
study was conducted according to the principles expressed in
the Declaration of Helsinki. This trial was registered at
clinicaltrials.gov as NCT01838239.
Lipid Profiling
Compositional lipid analysis was performed by Lipomics
Technologies, Inc. (West Sacramento, CA) according to the
method described by Watkins et al [27]. Coefficients of
variation for this analysis were reported previously [28]. Briefly,
the lipids from plasma (200 µL) were extracted using a
modified Folch extraction in chloroform:methanol (2:1 v/v) [29].
Extracted lipids were separated by preparative high-pressure
liquid chromatography into 7 lipid classes— free fatty acids
(FFA), diacylglycerol (DG), triacylglycerol (TG), cholesterol
ester (CE), lysophosphatidylcholine (LY), phosphatidylcholine
(PC), and phosphatidylethanolamine (PE). The FA from all lipid
classes were trans-esterified in 3 N methanolic HCl. The
resulting FA methyl esters were extracted and analyzed by gas
chromatography using an Agilent 6890 gas chromatograph
(Palo Alto, CA) equipped with a 30-m HP-88 capillary column
and a flame-ionization detector. The following FA were
quantified in each lipid class and summed in order to obtain
total lipid class quantities: 14:0, 15:0, 16:0, 18:0, 20:0, 22:0,
24:0, 14:1n5, 16:1n7, t16:1n7, 18:1n9, t18:1n9, 18:1n7, 18:2n6,
t18:2n6, 18:3n6, 18:3n3, 18:4n3, 20:1n9, 20:2n6, 20:3n9,
20:3n6, 20:4n6, 20:3n3, 20:4n3, 20:5n3, 22:1n9, 22:2n6,
22:4n6, 22:5n3, 22:6n3, 24:1n9, and 24:6n3, and the
plasmalogen derivatives of 16:0, 18:0, 18:1n9, and 18:1n7
expressed as dm16:0, dm18:0, dm18:1n9, and dm18:1n7
respectively. Each individual FA was quantified as nmol FA/g
plasma. Results are expressed as mean ± SD. All univariate
and multivariate statistical analyses were performed using the
quantitative data. Mol % baseline data are presented in Table 1
and changes in mol % composition of key fatty acids are
presented in the results in order to be able to relate these
results to published literature, which for the most part reports
mol % data.
Table 1. Subject characteristics1.
Subject ID 202 203 206 207 212 214 218 220 222 225 227 231 Mean (SD)
Age 26 31 33 32 26 21 35 55 28 34 32 28 31 (8.)
Gender F F F F M F M M F M F F –
Height (m) 1.75 1.57 1.63 1.73 1.75 1.63 1.83 1.70 1.60 1.91 1.55 1.63 1.7 (0.1)
Weight (kg) 66 49 69 64 80 55 94 65 53 97 53 50 66 (17)
BMI (kg/m2) 22 20 26 21 26 21 28 22 21 27 22 19 23 (3)
Baseline PC EPA%2 0.8 0.4 1.0 1.6 1.1 0.2 1.7 0.5 0.6 0.6 0.7 1.0 0.9 (0.5)
Baseline PC DHA%2 2.4 3.0 4.0 4.0 4.1 2.1 4.5 1.9 4.4 2.8 4.7 3.1 3.4 (1)
Baseline PC ARA%2 6.9 7.5 14.2 10.5 12.1 8.0 11.2 11.3 9.3 9.8 9.2 8.1 9.8 (2.1)
Baseline PC EPA/ARA 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.2 (0.04)
Baseline PE EPA%2 0.7 0.5 1.6 0.7 1.7 0.5 2.0 0.4 0.7 1.1 0.8 1.4 1.0 (0.6)
Baseline PE DHA%2 5.2 5.4 8.4 6.7 7.7 6.0 7.2 3.3 8.3 7.5 6.5 5.8 6.5 (1.5)
Baseline PE ARA%2 23 26 30 26 27 25 28 27 27 27 26 26.9 27 (1.7)
Baseline PE EPA/ARA 0.03 0.02 0.06 0.03 0.06 0.02 0.07 0.01 0.03 0.04 0.03 0.05 0.04 (0.02)
1 PC, phosphatidylcholine; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; ARA, arachidonic acid; phosphatidylethanolamine.
2 Fatty acids are presented as mol % of total fatty acids within each lipid class
doi: 10.1371/journal.pone.0076575.t001
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Oxylipin Profiling
Oxylipins were analyzed as described previously [30]. Briefly,
the plasma samples were subjected to solid phase extraction
(SPE) on 60 mg Waters Oasis-HLB cartridges (Milford, MA).
The elutions from the SPE cartridges were evaporated using a
Speedvac (Jouan, St-Herblain, France) and reconstituted in a
200 nM 1-cyclohexyl ureido, 3-dodecanoic acid (CUDA) in a
methanol solution. An Agilent 1200 SL (Agilent Corporation,
Palo Alto, CA) equipped with a 2.1 × 150 mm Eclipse Plus C18
column with a 1.8 μm particle size (Agilent Corporation, Palo
Alto, CA) was used for liquid chromatography with the following
conditions: the autosampler was kept at 4 °C, mobile phase A
was water with 0.1% glacial acetic acid, mobile phase B was
acetonitrile/methanol (84:16) with 0.1% glacial acetic acid,
gradient elution was performed at a flow rate of 250 μL/min.
Chromatography was optimized to separate all analytes in 21.5
min according to their polarity with the most polar analytes,
prostaglandins and leukotrienes eluting first, followed by the
hydroxy and epoxy fatty acids. The column was connected to a
4000 QTrap tandem mass spectrometer (Applied Biosystems
Instrument Corporation, Foster City, CA) equipped with an
electrospray source (Turbo V). The instrument was operated in
negative multiple reaction monitor (MRM) mode. The optimized
chromatographic conditions and the MRM transitions, as well
as extraction efficiencies and validation (including coefficients
of variation) were reported previously [30]. Quality control
samples were analyzed at a minimum frequency of 10 hours to
ensure stability of the analytical calibration throughout the
analysis. Analyst software 1.4.2 was used to quantify the peaks
according to the standard curves. A total of 87 oxylipins were
measured by this method and are shown in a pathway map
(Figure S1).
Lipoprotein Profiling
Lipoprotein profiling was performed by LipoScience Inc.
(Raleigh, NC) using NMR spectroscopy and the LipoProfile-3
algorithm, which included measurement of the following
parameters: VLDL & Chylomicron Particles (total), Large VLDL
& Chylomicrons Particles, Medium VLDL Particles, Small VLDL
Particles, LDL Particles (total), IDL Particles, Large LDL
Particles, Small LDL Particles (total), Medium Small LDL
Particles, Very Small LDL Particles, HDL Particles (total), Large
HDL Particles, Medium HDL Particles, and Small HDL Particles
reported in nmol/L; VLDL Size, LDL Size, and HDL Size
reported in nm; and Triglyceride (total), VLDL & Chylomicron
Triglyceride (total), and HDL Cholesterol (total) reported in
mg/dL. The lipoprotein particle concentrations were quantified
from the amplitudes of the lipid methyl group NMR signals
according to previously published and validated methods [31].
Univariate Statistical Analysis
Data were tested for normality and pre-processed to account
for the high data density of the metabolomic approach used in
this study as described by Zivkovic et al. [28]. Metabolites with
>33% missing observations or that were not detected (i.e. were
below level of quantitation) were excluded from analysis.
Change-detection plots were used to determine whether the
observed signal was greater than that which could be expected
by chance (noise). All metabolite data were assessed for
normality with histograms. When non-normality was detected,
values were log2 transformed prior to analysis. The Bonferroni
correction was used to correct for multiple testing in this
lipidomic data set containing a total of 261 variables.
Differences were considered significant at the adjusted level of
α ≤ 0.0002. Paired t-tests were conducted to examine the
changes in individual metabolites from pre to post intervention.
Weight-adjusted EPA and DHA dose were calculated as the
total amount of EPA and DHA in the daily supplement
respectively, divided by each subject’s weight in kg.
Percentage change (% change) was calculated as (Post-
Pre)/Pre * 100. Standard least squares linear regressions were
run for each metabolite adjusting for age, gender, body weight,
and BMI. Pearson’s correlations were performed to assess
correlations between 1) baseline values and % change in all of
the metabolites, 2) % change in the supplemented FA (EPA
and DHA) and age, body weight, BMI, and 3) % change in
oxylipin precursors (ARA, EPA, and DHA) and % change in
oxylipin products and lipoprotein particle numbers and sizes. T-
tests were performed to assess differences in % change in
metabolites between male subjects and female subjects. Diet
records were analyzed by Nutrihand software (Nutrihand Inc.,
Soraya,CA). Diet records were imported into the software and
average values for macronutrients were calculated for all
subjects with available records. Values for the week prior to
beginning the intervention and at the end of the intervention
were compared by paired t-test. All statistics were performed
using Microsoft Excel and JMP statistical software (SAS
Institute Inc., Cary, NC).
Multivariate Statistical Analysis
Multivariate statistical analysis was performed using several
different methods, all available in the software SIMCA 13
(Umetrics, Umeå, Sweden). Principal component analysis
(PCA) was used to identify patterns in the data [32].
Regression analysis in terms of orthogonal projections to latent
structures discriminant analysis (OPLS-DA) was used to
investigate relationships in the data [33]. Orthogonal 2
projections to latent structures (O2PLS) was used to
investigate co-dependencies in the data [34]. In applying these
methods, the complexity of the data set was reduced, thereby
facilitating interpretation of the variability in the lipidomic profile.
This was done by extracting systematic variability into model
components, plotted against each other. The position of each
subject in the resulting coordinate system (score plot) was
determined by his or her own profile of variables in relation to
the other subjects’ profiles. The contribution of each variable to
the positioning of the subjects was calculated, and the resulting
loading values (in a loading plot) were used to interpret
patterns (PCA), relationships (OPLS-DA), and co-
dependencies (O2PLS) in the data. In other words, for the
PCA, systematic data variability was extracted and the
information was summarized in principal components and then
the relationship between this systematic variability and sample
collection time point (pre and post supplementation) was
investigated in OPLS-DA. Finally, in O2PLS, this pre vs. post
relationship between subsets of variables was further
Lipidomics of Response to Omega-3 Fatty Acids
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scrutinized to uncover co-dependencies among groups of
variables. Model validity was assessed by the amount of
systematic variation among the variables that were captured by
the model (R2X(cum) and (R2Y(cum)), the predictive ability of
the model (Q2(cum)), and p-values calculated by ANOVA
based on the cross-validated score vectors (CV-ANOVA) [35].
All data were scaled to unit variance and mean-centered before
modelling in order to prevent biased results due to the wide
range of numerical values displayed between the different
variables.
Results
Out of the 13 subjects who were enrolled, 1 subject dropped
out after the first day of the study due to gastrointestinal
symptoms (diarrhea) that may or may not have been related to
the intervention. The 12 remaining subjects included in the
study completed the entire regimen and none reported adverse
effects or problems in consuming the quantities of fish oil
administered. The subjects’ mean (+/- SD) baseline mol %
composition of key FA was: PC EPA 0.9% (0.5), PC DHA 3.4%
(1), PC ARA 9.8% (2.1), PC EPA/ARA ratio 0.2 (0.04), PE EPA
1.0% (0.6), PE DHA 6.5% (1.5), PE ARA 27% (1.7), and PE
EPA/ARA ratio 0.04 (0.02), as shown in Table 1. The mean (+/-
SD) fold-increase in mol % composition of key FA was: PC
EPA 6.7 (5.1), PC DHA 0.88 (0.59), PE EPA 5.5 (3.7), PE DHA
0.47 (0.45).
Five out of the 12 subjects provided dietary records. These
were analyzed by Nutrihand software and the averages of
estimated intakes of macronutrients, some of the key
micronutrients related to antioxidant function (i.e. vitamin C,
vitamin E, vitamin A), and FA (i.e. ALA, LA, ARA, EPA and
DHA as well as totals for saturated, monounsaturated, and
polyunsaturated FA) were assessed by paired t-test for diet
records provided before vs. after the intervention. The results
are reported in Table S1. There were no significant changes in
diet except the estimated intake of 18:2n6 was higher pre vs.
post intervention (mean ± SD: 3.65 ± 2.27 g/d pre vs. 0.90 ±
1.56 g/d post; p = 0.03) in these 5 subjects.
Variables that were excluded from analysis because they
either had >33% missing variables or were not detected (i.e.
were below the limit of quantitation) are listed in Table S2.
Multivariate Analysis
PCA.  Data examined by PCA produced strong models with
regard to R2X(cum) for the complete lipidomic profile, oxylipins,
and lipoprotein profiles (Figures S2, S3, and S4), as well as for
each lipid class (data not shown). A summary of model
assessment parameters (for all models included in the study) is
found in Table S3. Lipidomic (Figure S2) and oxylipin (Figure
S3) profiles were clearly separated by time point, with pre data
for all subjects grouping together, and post data for all subjects
grouping together, except for two individuals (202 and 220)
with different lipidomic profiles compared to the rest of the
subjects. Gender, age, weight, BMI, and weight adjusted EPA
and DHA dose, displayed loading values close to zero, and
were therefore not regarded as influential variables on the time
point separation in either of the models obtained for complete
lipidomic or oxylipin profiles. On the other hand, the lipoprotein
profiles (Figure S4) were not strongly separated by time point,
but instead by gender with sufficient loading values displayed
for gender to drive this separation.
However, the predictive power of these PCA analyses was in
general weak (0.13 < Q2(cum) < 0.56). Two different
approaches were taken to better understand this observation:
further multivariate examination by OPLS-DA and visualization
of individual responses followed by univariate statistical
analysis. The OPLS-DA analysis was performed in order to
understand which changes were consistent among all of the
subjects, whereas the visualization and univariate analysis was
performed in order to understand the changes that were
inconsistent among subjects.
OPLS-DA and O2PLS Analysis.  Lipidomic Profiles:
Statistical examination of the total lipidomic data with OPLS-
DA, revealed a significant difference (p = 0.00007) between
lipidomic profiles pre and post administration with ω3 (Figure
1a). The subjects were divided into two groups (pre and post)
along the first component (x-axis), capturing most of the
variability in the data set related to the time point of sample
collection (14%). EPA and DHA incorporated into PC, CE, PE,
TG, LY, total ω3 FA in PE, PC, CE and PC, as well as CYP-
products of EPA and DHA were among the most influential
species of the post-profile (Table S4).
Interestingly, this OPLS-DA analysis highlighted that two
subjects, 202 and 220, separated from the rest of the subjects
along the second component (y-axis), which captured most of
the orthogonal variability, unrelated to time point (16%). The
reason for this separation was not revealed in any of the PCA
models for each lipid class, oxylipins, or lipoproteins.
Figure 1.  Lipidomic (A) and lipoprotein (B) profiles
summarized as scores (t(1) and to(1)) calculated by OPLS-
DA.  All participants displayed altered lipidomic profiles pre
(grey circles) vs. post (black circles) supplementation (A).
Furthermore, the subjects displayed gender-specific lipoprotein
profiles, female (black circles) and male (grey circles), both
before and after intervention (B).
doi: 10.1371/journal.pone.0076575.g001
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Therefore, identification of characteristics in common to both
202 and 220 was accomplished by detecting influential species
to the orthogonal component (y-axis) in Figure 1a in order to
interrogate the drivers separating subjects 202 and 220 from
the rest of the group. A selection of the 35 most influential
species to the orthogonal component revealed the substantial
contribution of monounsaturated FA, n7 FA, and n9 FA, and
other indicators of high de novo lipid synthesis (Table S5). A
PCA model of these selected variables showed a clear
separation of subjects 202 and 220 from the rest of the group
(Figure 2). Hence, the deviating behavior of subject 202 and
220 compared to the rest of the participants in the study was
due to their increased markers of de novo lipid synthesis.
Interestingly, neither the lipoprotein profile alone, nor the
lipoprotein markers of de novo lipid synthesis displayed a
difference that was specific to subjects 202 and 220. Hence,
the variability in the lipidomic profiles not related to time point
(pre vs. post) revealed by the orthogonal component in Figure
1a, which was responsible for the exclusive behavior of
subjects 202 and 220, was partly offset by the gender aspect of
the lipoprotein profile (Figure S4).
The statistical interpretations of lipid changes across the
subject population were extended by univariate analysis.
Paired t-tests of all of the variables pre vs. post
supplementation showed that PC, CE, PE, TG, and LY EPA
and DHA had the largest and most consistent changes in
response to intervention, with magnitude of change on the
order of 2-, to 6-fold (Table 2). EPA and DHA diols and one
DHA epoxide, plus 5-oxo-ETE also increased significantly,
whereas the ω6 FA LA and its elongation and desaturation
intermediates 18:3n6, 20:3n6, 22:4n6, and 22:5n6 in PC, PE
and CE decreased. Table S6 shows additional metabolites that
were increased or decreased post supplementation significant
at an α≤0.005, which is not as stringent as the multiple
comparison adjusted α of ≤ 0.0002. Notably, EPA LOX
metabolites 12-HEPE, 15-HEPE and 5-HEPE increased; the
EPA elongation product 22:5n3 increased in PC, CE, and FFA;
several additional DHA diols increased; LA and ALA LOX
metabolites 9-HODE and 9-oxo-ODE, and 13-HOTrE and 9-
HOTrE respectively, decreased; total TG as well as the number
of VLDL and chylomicron particles and their TG content
decreased; the auto-oxidation markers EKODE decreased; and
PC20:3n9, a marker of essential fatty acid deficiency, also
decreased.
Oxylipin Profiles: OPLS-DA was also used to further evaluate
the specific responses in oxylipin profiles. A significant
difference (p = 0.000002) was detected between oxylipin
profiles pre and post supplementation (Figure S5). CYP-
products, especially those derived from DHA and EPA, as well
as a subset of the total possible LOX products of EPA were
increased post supplementation (Figure 3a). Metabolites were
grouped according to pathway and shown in a loading plot.
Within each pathway, the metabolites are ordered by
increasing influence to the differences associated with the post
intervention profile. Hence, metabolites below the origin
dominated the pre-intervention profile and vice versa. The
larger the absolute value of the metabolite in the OPLS-DA
analysis, the more influential in either the pre-intervention
profile (negative values) or post-intervention profile (positive
values) the metabolite was. The CYP pathway contained the
most influential metabolites of the post profile, shown far to the
left in Figure 3a, followed by LOX and COX pathway
metabolites.
Computational methods were then applied to interrogate the
specific effects of each ω3 FA. The co-dependency between
oxylipin profiles and DHA and EPA incorporated into different
lipid classes was investigated in more depth by O2PLS (Figure
3b). The components summarizing most of the oxylipin profile
Figure 2.  PCA score plot of the 35 variables most
influential to the orthogonal component in Figure
1a.  There was a pattern among the data separating subject
202 and 220 (black circles) from the rest of the subjects (grey
circles).
doi: 10.1371/journal.pone.0076575.g002
Table 2. Variables significantly different by paired t-test pre
vs. post intervention at α ≤ 0.0002 (adjusted for multiple
comparisons).
Metabolite Mean Pre SD Pre Mean Post SD Post P-value
Metabolites that increased post supplementation
PC22:6n3 (nmol/g) 127 34.7 215 36.6 < 0.0001
PC20:5n3 (nmol/g) 32.8 19.9 182.2 53.9 < 0.0001
CE20:5n3 (nmol/g) 27.0 17.8 152.1 59.3 < 0.0001
TG22:6n3 (nmol/g) 13.5 6.63 69.6 26.5 < 0.0001
TG22:5n3 (nmol/g) 8.18 2.50 21.8 9.85 0.0001
TG20:5n3 (nmol/g) 4.87 3.53 50.4 21.0 < 0.0001
PE20:5n3 (nmol/g) 4.44 2.34 22.8 9.25 < 0.0001
LY20:5n3 (nmol/g) 0.588 0.413 3.28 1.42 < 0.0001
17,18-DiHETE (nmol/L) 0.476 0.155 2.68 1.35 < 0.0001
5-oxo-ETE (nmol/L) 0.458 0.122 3.46 1.91 < 0.0001
16,17-DiHDPE (nmol/L) 0.245 0.075 0.492 0.170 0.0002
10(11)-EpDPE (nmol/L) 0.162 0.094 0.548 0.271 < 0.0001
8,9-DiHETE (nmol/L) 0.069 0.031 0.457 0.223 < 0.0001
14,15-DiHETE (nmol/L) 0.060 0.027 0.413 0.221 < 0.0001
16(17)-EpDPE (nmol/L) 0.056 0.046 0.222 0.121 0.0001
11,12-DiHETE (nmol/L) 0.040 0.022 0.243 0.115 < 0.0001
Metabolites that decreased post supplementation
PC18:2n6 (nmol/g) 958.54 212.13 779.99 206.65 0.0002
CE18:3n6 (nmol/g) 25.6 12.6 13.2 7.28 0.0001
PC22:4n6 (nmol/g) 12.0 2.54 6.95 2.15 < 0.0001
PE20:3n6 (nmol/g) 8.59 2.91 5.32 2.45 < 0.0001
PC22:5n6 (nmol/g) 8.49 3.43 3.86 1.52 < 0.0001
doi: 10.1371/journal.pone.0076575.t002
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variability (x-axis) and DHA and EPA profile variability (y-axis)
were plotted against each other. There was a strong overall
correlation (r2=0.93), as well as individual correlation to each
lipid class (Table S7). Hence, there was a joint variation among
the oxylipins and DHA and EPA, which covered 30% of the
total oxylipin and 66% of the total DHA and EPA variation. The
major oxylipins correlating to EPA and DHA were CYP
products of EPA and DHA (DiHETEs, and EpDPEs and
DiHDPEs respectively) (Table S8), in accordance with the most
influential species responsible for the statistically significant
changes in the lipidomic profile pre vs. post supplementation.
By extracting the 20% of the systematic variation in the oxylipin
profile that was not related to EPA and DHA variation, LOX-
products of LA (HODEs), ALA (HOTrEs), and ARA (HETEs)
were detected to have little or no correlation with EPA and DHA
(Table S9), meaning these metabolites were not responsive to
the ω3 intervention.
Lipoprotein Profiles: The lipoprotein profiles of individuals
prior to and after ω3 intervention were examined statistically
using OPLS-DA. These analyses found a large and significant
separation of individuals according to gender (Figure 1b).
Females showed higher values for HDL size, LDL size, large
LDL particles, HDL cholesterol, large HDL particles, VLDL size,
and medium VLDL particles, while males had higher total TG,
total LDL particles, very small LDL particles, small LDL
particles, medium small LDL particles, total VLDL and
chylomicron particles, IDL particles, HDL particles, small VLDL
particles, large VLDL and chylomicron particles, and small HDL
particles.
Figure 3.  Contribution of each oxylipin to the pre (below
origin) and post (above origin) profiles calculated by
OPLS-DA (A).  The CYP pathway (black) was the most
responsive pathway, followed by the LOX pathway (light grey),
and COX pathway (dark grey). Correlation between the oxylipin




Individual Variation in ARA Metabolites.   Examining the
responses of subjects as individuals was revealing. Several
ARA derived eicosanoids known to be important in
inflammatory disease processes including the COX-derived
prostaglandin PGE2 and thromboxane TXB2, as well as the
LOX-derived 12-hydroxyeicosatetraenoic acid (12-HETE)
exemplify this variability. A bar graph of % change in PGE2
showed that in 6 out of 12 subjects (202, 203, 207, 212, 218,
222) PGE2 decreased, and in 6 out of 12 subjects (206, 214,
220, 225, 227, 231) PGE2 increased in response to the
intervention (Figure 4a). The magnitude of change ranged from
a 76% decrease in subject 207 to an 85% increase in subject
214. Percentage change in PGE2 was not correlated with %
change or baseline values of ARA. However, % change in ARA
across several lipid classes was positively correlated with %
changes in PGD2 and the HETEs (5-, 8-, 9-, and 12-HETE)
(Table 3). Percentage change in PC ARA was strongly
negatively correlated with % change in PGF2α such that the
greater the decrease in the PC ARA content, the higher the
increase in PGF2α (Figure 5a). The response in PGF2α was also
diverse across the 12 subjects, from 10-70% decreases in 9 of
the subjects to 5-60% increases in 3 of the subjects (Figure
S6).
TXB2 also decreased in 5 subjects (202, 203, 207, 218, 222),
stayed about the same in 2 subjects (212 and 227), and
increased in 5 subjects (206, 214, 220, 225, 231) (Figure 4b).
The magnitude of change ranged from a decrease of 84% in
subject 207 to an increase of 260% in subject 206. Percentage
change in TXB2 was positively correlated with % change in PE
ARA however, the p-value did not meet the Bonferroni-adjusted
Figure 4.  Bar graphs of each individual subject’s %
change in the following arachidonic acid (ARA, 20:4n6)
metabolites (subjects ordered by direction and magnitude
of response on x axis): A) the cyclooxygenase (COX)
metabolite prostaglandin E2 (PGE2); B) the COX metabolite
thromboxane B2 (TXB2); C) ARA concentrations within the
phosphatidylethanolamine (PE) lipid class; and D) the
lipoxygenase metabolite 12-hidroxyeicosatetraenoic acid
(12-HETE).  
doi: 10.1371/journal.pone.0076575.g004
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Table 3. Correlations between % change in arachidonic
acid (ARA, 20:4n6), eicosapentaenoic acid (EPA, 20:5n3)
and docosahexaenoic acid (DHA, 22:6n3), their oxylipin
products, and baseline values at p ≤ 0.05.
Variable X Variable Y RsquareP-value
% Change CE20:4n6 % Change PGF2α -0.501 0.015
% Change PE20:4n6 % Change PGD2 0.378 0.033
% Change PC20:4n6 % Change PGF2α -0.715 0.001
% Change PE20:4n6 % Change TXB2 0.469 0.014
% Change PE20:4n6 % Change 12-HEPE 0.402 0.027
% Change PE20:4n6 % Change CE22:6n3 0.506 0.021
% Change FFA20:4n6 % Change 5-HETE 0.561 0.005
% Change PE20:4n6 % Change 8-HETE 0.340 0.047
% Change TG20:4n6 % Change 9-HETE 0.522 0.008
% Change PE20:4n6 % Change 12-HETE 0.427 0.021
% Change FFA20:4n6 % Change 15(S)-HETrE 0.383 0.032
% Change FFA20:4n6 % Change 5-HEPE 0.758 0.0002
Body Weight (kg) % Change 8,9-DiHETE -0.446 0.018
Body Weight (kg) % Change 17,18-DiHETE -0.521 0.012a
Body Weight (kg) % Change 10,11-DiHDPE -0.477 0.013
Body Weight (kg) % Change 15-HEPE -0.408 0.025
Body Weight (kg) % Change 17-HDoHE -0.353 0.042
Body Weight (kg) % Change Medium VLDLParticles 0.394 0.039
Body Weight (kg) % Change HDL Size (nm) -0.326 0.052
Body Weight (kg) % Change DG22:6n3 -0.525 0.018
Body Weight (kg) % Change FFA18:3n6 -0.414 0.033
Body Weight (kg) % Change FFA20:5n3 -0.519 0.008
Body Weight (kg) % Change FFA22:6n3 -0.406 0.026
Body Weight (kg) % Change PE22:0 0.476 0.027
Body Weight (kg) % Change TG22:0 -0.484 0.025
Body Weight (kg) Baseline PE EPA% 0.363 0.038
Body Weight (kg) Baseline PE EPA/ARA 0.325 0.053
BMI Baseline PC ARA% 0.431 0.020
BMI Baseline PE EPA% 0.496 0.011
BMI Baseline PE EPA/ARA 0.461 0.015
% Change FFA20:5n3 % Change 8,9-DiHETE 0.439 0.019
% Change FFA20:5n3 % Change 11,12-DiHETE 0.409 0.025
% Change DG20:5n3 % Change 14,15-DiHETE 0.691 0.003
% Change TG20:5n3 % Change 17,18-DiHETE 0.891 <0.0001b
% Change FFA20:5n3 % Change 17,18-DiHETE 0.344 0.045
% Change CE20:5n3 % Change 17,18-DiHETE 0.860 <0.0001b
% Change FFA20:5n3 % Change 5-HEPE 0.643 0.002
% Change CE20:5n3 % Change 15-HEPE 0.466 0.021
% Change FFA20:5n3 % Change 15-HEPE 0.666 0.001
% Change PC20:5n3 % Change 15-HEPE 0.452 0.017
% Change FFA22:6n3 % Change 10(11)-EpDPE 0.468 0.014
% Change FFA22:6n3 % Change 10,11-DiHDPE 0.820 0.0001
% Change FFA22:6n3 % Change 13,14-DiHDPE 0.488 0.011
% Change FFA22:6n3 % Change 16,17-DiHDPE 0.544 0.006
% Change TG22:6n3 % Change 19,20-DiHDPE 0.360 0.039
% Change FFA22:6n3 % Change 19,20-DiHDPE 0.432 0.020
% Change FFA22:6n3 % Change 17-HDoHE 0.690 0.001
% Change TG22:6n3 % Change 17-HDoHE 0.467 0.014
Baseline PC ARA% % Change 5-HEPE -0.350 0.043
Baseline PC ARA% % Change 15-HEPE -0.399 0.028
level of significance (p=0.01) and the R2 value was moderate
(r2=0.47) (Table 3). The % change in PE ARA across
individuals ranged from a 42% decrease in subject 203 to a
15% increase in subject 214 (Figure 4c). The ARA LOX
metabolite 12-HETE showed a similar pattern, with 12-HETE
increasing in 5 subjects (206, 214, 220, 225, 231), and
decreasing in 7 subjects (202, 203, 207, 212, 218, 222, 227)
Table 3 (continued).
Variable X Variable Y RsquareP-value
Baseline PE ARA% % Change PE22:6n3 -0.711 0.001c
Baseline PC EPA% % Change 5-HEPE -0.335 0.049
Baseline PC EPA% % Change 12-HEPE -0.344 0.045
Baseline PC EPA% % Change 15-HEPE -0.412 0.024
Baseline Medium VLDL
Particles % Change DG22:6n3 0.416 0.044
Baseline LDL Size % Change PC22:6n3 -0.372 0.035
Baseline HDL Size % Change PC22:6n3 -0.327 0.052
a Outlier removed: Subject 214
b Subject 214 was considered a hyperresponder and was kept in the analysis,
rather than being excluded as an outlier
c Outlier removed: Subject 220
doi: 10.1371/journal.pone.0076575.t003
Figure 5.  Correlations between: A) % change in
arachidonic acid (ARA, 20:4n6) cyclooxygenase metabolite
prostaglandin F2α (PGF2α) and % change in
phosphatidylcholine (PC) concentrations of ARA; B) %
change in eicosapentaenoic acid (EPA, 20:5n3) soluble
epoxide hydrolase (sEH) metabolite 17,18-
dihydroxyeicosatrienoic acid (17,18-DiHETE) and %
change in triglyceride (TG) concentrations of EPA; C) %
change in docosahexaenoic acid (DHA, 22:6n3) sEH
metabolite 10,11-dihydroxydocosapentaenoic acid (10,11-
DiHDPE) and % change in free fatty acid (FFA)
concentrations of DHA; D) % change in PE concentrations
of DHA and baseline PE ARA %.  
doi: 10.1371/journal.pone.0076575.g005
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(Figure 4d). The magnitude of change ranged from an 82%
decrease in subject 202 to a 143% increase in subject 206.
Individual Variation in EPA Metabolites.  The individual
variability was equally evident in the changes in ω3 FA derived
metabolites. The EPA LOX metabolite 12-
hydroxyeicosapentaenoic acid (12-HEPE) displayed a large
degree of variation from an 82% decrease in subject 207, to no
change in subject 202, to increases in the range of 50-100% in
subjects 222 and 218, to increases in the range of 300-1200%
in subjects 225, 227, 203, 212, and 231, to increases in the
range of 2000-5000% in subjects 220, 206, and 214 (Figure
6a). Interestingly, three subjects (206, 214, and 220) who had
high PGE2, TXB2, and 12-HETE also had high 12-HEPE
concentrations post intervention. Baseline PC EPA % was
negatively correlated with % change in 12-HEPE (Table 3),
although this correlation did not meet the Bonferroni-adjusted
p-value requirement for significance.
The EPA diol 17,18-DiHETE increases ranged from 140% in
subject 218 to 1947% in subject 214, an order of magnitude
difference (Figure 6b). This type of variation was observed
across the EPA and DHA epoxides and diols (Figure S6).
Percentage change in 17,18-DiHETE was highly correlated
with % change in EPA in the TG (Figure 5b) and CE lipid
classes with R2 values of 0.89 and 0.86 respectively and p-
values < 0.0002 (Table 3). Subject 214 was considered a
hyper-responder rather than an outlier and was therefore kept
in the analysis, but even when this subject was removed from
the analysis, the correlations remained (TG: p=0.002, r2=0.66;
CE: p=0.05; r2=0.4). EPA in the PC (Figure 6c) and PE (Figure
6d) lipid classes increased across all subjects however, to
different degrees, with increases in PC EPA ranging from as
Figure 6.  Bar graphs of each individual subject’s %
change in the following eicosapentaenoic acid (EPA,
20:5n3) metabolites (subjects ordered by direction and
magnitude of response on x axis): A) the lipoxygenase
metabolite 12-hydroxyeicosapentaenoic acid (12-HEPE); B)
the soluble epoxide hydrolase (sEH) metabolite 17,18-
dihydroxyeicosatrienoic acid (17,18-DiHETE); C)
phosphatidylcholine (PC) concentrations of EPA; and D)
phosphatidylethanolamine (PE) concentrations of EPA.  
doi: 10.1371/journal.pone.0076575.g006
low as 104% in subject 207 to as high as 3528% in subject
214. Subject 214 was a hyper-responder and had the highest
increases in all 4 metabolites (PC and PE EPA, 12-HEPE and
17,18-DiHETE).
Individual Variation in DHA Metabolites.  Responsiveness
in the DHA metabolites also varied across individual subjects.
Percentage change in the DHA LOX metabolite 17-HDoHE
ranged from a decrease of 60% in subject 212 to an increase
of 470% in subject 203 (Figure 7a). Percentage change in 17-
HDoHE was positively correlated with % change in both FFA
and TG DHA, as well as being negatively correlated with body
weight (Table 3). The % change in DHA diol 10,11-DiHDPE
ranged from essentially no change (-4% in subject 218) to an
increase of 589% in subject 227 (Figure 7b). 10,11-DiHDPE
was positively correlated with DHA in the FFA lipid class
(Figure 5c) and negatively correlated with body weight (Table
3). Changes in DHA across lipid classes also varied, as
exemplified by PE and TG. PE DHA ranged in % change from
essentially no change (-4 to -6% in subjects 218, 222, and 225)
to an increase of 187% in subject 220 (Figure 7c), whereas TG
DHA ranged in % change from about 200% in subjects 206,
207, 212, 218, 222, and 225 to 1890% in subject 214 (Figure
7d). Baseline PE ARA% was negatively correlated with PE
DHA (Table 3) such that the lower the starting PE ARA% the
higher the increase in PE DHA (Figure 5d).
Age, Gender, Body Mass, and Baseline Effects.  This was
a pilot study not specifically designed and powered to adjust for
covariates. However, for exploratory purposes, standard least
squares linear regressions on the % change of all variables
were run and adjusted for age, gender, body weight, and BMI,
and those that reached p-values < 0.05 for the overall model
Figure 7.  Bar graphs of each individual subject’s %
change in the following docosahexaenoic acid (DHA,
22:6n3) metabolites (subjects ordered by direction and
magnitude of response on x axis): A) the lipoxygenase
metabolite 17-hydroxy docosahexaenoic acid (17-HDoHE);
B) the soluble epoxide hydrolase (sEH) metabolite 10,11-
dihydroxydocosapentaenoic acid (10,11-DiHDPE); C)
phosphatidylethanolamine (PE) concentrations of DHA;
and D) triglyceride (TG) concentrations of DHA.  
doi: 10.1371/journal.pone.0076575.g007
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were reported in Table S10. None of the p-values were below
the Bonferroni-adjusted level of α < 0.0002 for the overall
model. However, there were some notable effects including a
strong influence of age, body weight, and BMI on the response
in PC:18:0. Percentage change in PC18:0 was negatively
correlated with age and body weight, and positively correlated
with BMI. Other notable effects included the effects of age,
gender and body weight on response in CE18:1n9, the effects
of age and body weight on response in large HDL particles,
and the effect of BMI on the response in TG22:0 and
TG22:1n9. Notably, responses in neither the FA precursors
(i.e. EPA, DHA, and ARA) nor their oxylipin products were
influenced by age, gender, body weight or BMI.
There were several gender effects observed when response
in the metabolites was assessed by t-test comparing % change
in females vs. males (Table S11). Response to the treatment in
elongation products varied between females and males.
Notably, whereas TG22:0 increased by about 50% in females,
it decreased by the same amount in males. Similarly, TG
20:1n9 and TG22:1n9 increased in females and decreased in
males. There were also some differences in lipoprotein particle
numbers and sizes, as expected given the multivariate analysis
results. Large VLDL & chylomicron particles decreased more in
males, whereas medium VLDL particles decreased in the
females but increased in males. The response in the ARA,
EPA, and DHA epoxides and diols was also different between
genders. Females had much higher increases in all EPA and
DHA diols, with lesser decreases in ARA diols. Females also
had higher weight-adjusted EPA and DHA doses.
Discussion
In this study comprehensive multi-platform lipidomic profiling
of 12 healthy individuals pre vs. post intervention with a
proscribed dose of fish oil enriched in ω3 FA was performed in
order to understand both the universal aspects of response to
these lipids in healthy people and the variation in response
among individuals. Both multivariate and univariate statistical
approaches were applied to determine the consistent and
variable aspects of response among these subjects in FA,
oxylipins, and lipoproteins.
We found a decrease of about 24% in plasma TG
(p=0.0005), which is in agreement with previous studies and
meta-analyses showing approximately 25–30% decreases in
TG in healthy subjects in response to 3-4 g/d EPA + DHA
[36,37]. VLDL and chylomicron particles also decreased by
about 32% (p=0.005). Lipoprotein profiles were more indicative
of gender differences rather than response to intervention.
Female subjects had lipoprotein profiles that were more
consistent with traditional markers of lower risk for heart
disease (i.e. more and larger HDL, larger LDL) whereas male
subjects had lipoprotein profiles that are associated with classic
indicators of higher risk (i.e. more TG and LDL, more small LDL
and small HDL particles). These findings are in agreement with
previous findings of higher large HDL, and lower small and
medium LDL, large and medium VLDL, and small HDL in
women than in men [38]. In female subjects, medium VLDL
decreased whereas in male subjects medium VLDL increased
and there were greater decreases in VLDL and chylomicron
particles. Previous studies have shown that ω3 shift VLDL
toward smaller particles in men [39]. A previous study found
that HDL decreased in women whereas TG decreased in men,
however, this was after a much higher dose of EPA (4.5 g/d)
and slightly higher dose of DHA (1.9 g/d) than in this study [40].
A recent study supplementing overweight subjects with almost
exactly the same fish oil from Ocean Nutrition with the same
amount of EPA but slightly lower DHA for the same duration (6
weeks) found that TG decreased by 11-25%, but that there
were no effects on LDL, HDL, ApoB, insulin, or CRP when they
examined men and women together [37]. However, they found
that the intervention increased HDL in women, and they also
found that apoE genotype was associated with fasting glucose,
insulin, and CRP responses [37]. Thus it is likely that genetic
differences in addition to gender play a role in the differential
responses to ω3 FA.
Multivariate analyses created strong models of pre vs. post
differences in FA and oxylipin profiles, with plasma levels of
EPA and DHA incorporated into different lipid classes and CYP
products of EPA and DHA (DiHETEs, and EpDPEs and
DiHDPEs respectively) increasing in all subjects. Some
elongation and desaturation metabolites of ω6 FA decreased,
confirming ω3 outcompeted the ω6 in the desaturation and
elongation pathways, as has been observed previously [41].
The relative proportion of phospholipid EPA increased on
average 6–7-fold, and phospholipid DHA 0.5–1-fold. This is in
agreement with previous studies, which showed similar
increases in phospholipid EPA and DHA [20,22,42]. Delta-5
desaturase (FADS1) and delta-6 desaturase (FADS2)
polymorphisms have been shown to be highly influential in
plasma, red blood cell, and milk EPA and DHA composition
[43-47], and may have played a role in the divergent EPA and
DHA levels among subjects in this study. Consistent increases
in the EPA and DHA CYP products (EPA diols and DHA
epoxides and diols) have been observed previously in
response to long-chain ω3 supplementation in patients [21,22]
and in healthy controls [20,22,42]. These metabolites
(DHETEs, EpDPEs, DHDPEs) may be particularly informative
because of their apparent dose-response relationship, and
could be useful as markers of ω3 FA intake and
responsiveness. Decreases in ARA epoxides and diols were
not found to be statistically significant after correction for
multiple comparisons in this study.
The inter-individual variation in all metabolites in response to
the ω3 FA intervention was explicitly examined, and was
surprisingly high. In half of the subjects, not grouped according
to gender or bodyweight, ARA-derived eicosanoids PGE2,
TXB2, and 12-HETE increased post intervention whereas in the
other half, the expected decrease in these metabolites was
observed. PGF2α decreased in 9 but increased in 3 subjects.
Previous studies (in vitro, animal, and human) have found fish
oil and ω3 FA reduce ARA-derived eicosanoids [14-18,48-51].
A recent study supplementing healthy men with similar EPA
and DHA doses as in this study found increased TXB2 and
PGF2α and no change in 12-HETE but highlighted high inter-
individual variability in response to the fish oil [52]. These
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authors also found that 12-HETE decreased in 2 participants
but increased in 8 others [52].
There were no correlations between changes in PGE2 and
either baseline ARA or % change in ARA. Percentage change
in ARA was, however, correlated with % change in PGD2,
TXB2, PGF2α and the HETEs. The changes in ARA were not
universal across subjects, with % change in, for instance, PE
ARA ranging from a 42% decrease to a 15% increase. The
dietary data from the 5 subjects who supplied adequate diet
records did find modest changes in estimated intakes of LA,
and these could be related to some of the observed differences
in ARA concentration. However, given that ω3 FA inhibit LA
conversion to ARA, as confirmed by the observed reduction in
the intermediates 18:3n6 and 20:3n6, it is unlikely that dietary
LA conversion to ARA played a significant role in the variability
in ARA among subjects. Nonetheless, future studies will need
to more adequately control for the intake of LA and ARA in the
diet to completely account for diet as a potential source of
ARA, which could affect the overall effect of the ω3
intervention. It is possible that dietary records will not be
sufficiently accurate estimates of dietary FA intakes and that
alternative methods for controlling dietary FA composition will
be needed.
Whether the observed increases and decreases in plasma
levels of oxylipins correlate with actual disease outcomes or
are indicative of overall systemic inflammation is unknown. In
general, outcome studies have not yet related the abundance
of these important lipid mediators to either health or specific
diseases. Therefore it is unclear whether the changes in
concentration observed in this study – as much as a 6-fold
decrease in TXB2 in subject 207, or a 2.5-fold increase in TXB2
in subject 220, for example – are indicative of deviations from
normal that accurately predict an increase or decrease in
disease risk. Previous studies have found coefficients of
variation (CVs) in PGE2 on the order of 251% prior to ω3
intervention and 156% post intervention in asthmatics [22],
whereas the CVs for PGE2 in this study were 36% and 28%
respectively. Another study evaluating the human serum
metabolome found a CV of 76% for PGE2 among 70 healthy
subjects [53]. Thus, the variability in PGE2 among the healthy
subjects in this study was lower than in asthmatic subjects and
in a larger cohort of healthy subjects. Much still needs to be
learned about the fluctuations over time in these metabolites
among healthy individuals and in individuals with various
disease states in order to understand the significance of
observed changes in response to ω3 FA.
Even among the metabolites that ubiquitously increased in
all subjects, there was a high degree of inter-individual
variation in the magnitude of change. For example, EPA in PC
and PE ranged in its increase from 2-fold to 36-fold among
subjects. PE DHA ranged from no change to a 200% increase.
TG DHA ranged from 200% to 2000% increase. This variability
points to fundamental differences in metabolism that may be
anywhere along the chain of events from intestinal absorption
to incorporation into phospholipids to lipoprotein synthesis and
turnover. Previous studies investigating EPA and DHA
incorporation into serum or plasma lipid pools have shown
increases in the range of 4-fold to 8-fold at similar
supplementation doses as in the present study [54,55].
However, this study, as do most studies, reported total
phospholipid FA mol % composition rather than quantitative
concentrations within specific phospholipids or other lipid
classes as we did in the present study. Much as cholesterol
levels are diagnostic as absolute concentrations (mg/dL), larger
studies are needed to determine the range of normal
concentrations of the ω3 FA across the lipid classes and their
metabolites across healthy individuals, and the deviations in
the absolute concentrations that are associated with different
disease conditions and diets.
There were no significant correlations between baseline or %
change in EPA, DHA, or ARA and age, gender, body weight, or
BMI despite the fact that female subjects received higher
effective doses of EPA and DHA (i.e. weight-adjusted doses).
Similarly, there were no effects of age, gender, body weight, or
BMI on % change in ARA, EPA, and DHA or their oxylipin
products. However, there were some associations between
precursor FA within specific lipid pools and several
downstream oxylipin metabolites. Baseline PC EPA was
negatively correlated with % change in 12-HEPE such that the
lower the starting EPA concentration, the higher the increase in
12-HEPE. The EPA diol 17,18-DiHETE was strongly positively
correlated with % change in EPA in the TG and CE lipid
classes, but not the phospholipids. This metabolite appears to
be a consistent marker of dose-dependent EPA
supplementation. The lower the baseline PE ARA the higher
the increase in PE DHA. This suggests that some individuals
have high constitutive ARA in their PE that does not get
replaced by DHA, whereas in other individuals there is a higher
rate of replacement of ARA with DHA in this particular
phospholipid class. Percentage change in the DHA LOX
metabolite 17-HDoHE was positively correlated with % change
in TG and FFA DHA, and the DHA diol 10,11-DiHDPE was also
positively correlated with % change in FFA DHA. These data
highlight high individual variation in the extent of incorporation
of EPA and DHA into different plasma lipid pools and in the
subsequent production of downstream oxylipin metabolites
from these different pools. Further studies are needed to better
understand how EPA and DHA and their metabolites are
differentially metabolized in different dietary and genetic
backgrounds, and the implications of these differences in the
various outcomes related to ω3 interventions.
This was an exploratory/pilot study with 12 subjects, which
was not blinded and did not have a control arm, all of which are
potential limitations of the study. The current study was not
powered specifically to determine age, gender, body weight, or
BMI effects, thus our observations in this area are exploratory
in nature and highlight the need for further studies. This study
also did not adequately control for diet and exercise/physical
activity. We did not design this study explicitly to determine
clinically relevant health outcomes related to ω3 intervention.
Instead, our aim was to determine whether the comprehensive
profiling of lipid metabolism to assess response to ω3 FA could
be a useful approach for assessing individual responsiveness
and to identify specific metabolic phenotypes. We have
demonstrated that a comprehensive lipidomic approach does
indeed reveal those aspects of responsiveness to ω3 FA that
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are consistent across healthy individuals and those that are
variable. Future studies will need to determine the causes of
the high variability in certain aspects of metabolism, and the
implications of this variability on health outcomes so that the
goal of a more personalized approach can be realized.
Conclusions
Current intakes of ω3 FA in the U.S. are about 1.7 g/d out of
a total of 19 g/d of polyunsaturated FA including both ω6 and
ω3, with most of that being in the form of the 18C precursor
ALA [6]. Intakes of the long-chain EPA and DHA are only about
130 mg/d [6]. This represents a ratio of ω6:ω3 of 10:1, whereas
estimates of historic intakes are closer to 1:1 [56]. Thus ω3 FA
are generally deficient in Western diets and these dietary
deficiencies in ω3 FA may be contributing to the
preponderance of inflammatory diseases in the U.S. and
elsewhere. However, there is a lack of consensus about
whether and how to establish dietary recommendations for the
intake of ω3 due to conflicting findings in both observational
and intervention studies. A recent comprehensive update from
an expert panel concluded that a key knowledge gap in
understanding the effects of ω3 FA in modifying disease risk is
the ability to identify those groups of individuals for whom they
are beneficial and those for whom they are not beneficial, as
well as the effective dosages and formulations [57]. In the
present study we have shown that a comprehensive multi-
platform lipidomic approach, simultaneously measuring FA
within different lipid classes, oxylipins, and lipoprotein particle
size and distribution, is able to identify key differences in
response to ω3 intervention. Larger studies utilizing a similar
approach should address variation among men and women
with different genetic backgrounds, on different background
diets, and on different formulations and dosages of ω3 FA to
assess the effectiveness of ω3 interventions on modifying
metabolic, inflammatory, and lipoprotein profiles toward a
healthier phenotype.
Supporting Information
Figure S1.  Fatty acid precursors and their oxylipin
products. The fatty acids linoleic acid (LA, 18:2n6), α-linolenic
acid (ALA, 18:3n3), arachidonic acid (ARA, 20:4n6), dihomo-γ-
linolenic acid (DGLA, 20:3n6), eicosatrienoic acid (ETA,
20:3n9), eicosapentaenoic acid (EPA, 20:5n3), and
docosahexaenoic acid (DHA, 22:6n3) are precursors to a
number of oxylipin products produced via the cyclooxygenase
(COX), lipoxygenase (LOX), and cytochrome P 450 (CYP)
enzymes. The oxylipin products of the COX pathway include
prostaglandins (PGE1, PGD1, PGH2, PGF2α. PGE2, PGB2,
PGD2, PGJ2, 15-deoxy-PGJ2, PGI2, 6-keto-PGF1α, PGE3, PGH3,
and resolvin E1) and thromboxanes (TXA2, TXB2). The oxylipin
products of the LOX pathway include
hydroperoxyeicosatetraenoic acids (HpETEs) and
dihydroxyeicosatetraenoic acid (DiHETE), (further converted to
hydroxyeicosatetraenoic acids (HETEs)),
hydroxyoctadecadienoic acids (HOTrEs),
hydroxyeicosaptenaenoic acids (HEPEs), hydrox-
ydocosahexaenoic acid (17-HDoHE), and leukotrienes (LTA4,
LTB4, 20-OH-LTB4, 20-COOH-LTB4, 6-trans-LTB4, LTC4, LTD4,
LTE4, LTB3, LTB5) as well as the hydroxyoctadienoic acids
(HODEs), and trihydroxyoctamonoenoic acids (TriHOMEs).
The products of the CYP hydroxy (OH) pathway include 20-
HETE, and the products of the CYP epoxy pathway include the
epoxyeicosatrienoic acids (EETs), epoxyoctadecadienoic acids
(EpODEs), epoxyoctamonoe- noic acids (EpOMEs),
epoxyeicosatetreaenoic acids (EpETEs), and
epoxydocosapentaenoic acids (EpDPEs), as well as the
downstream soluble epoxide hydrolase (sEH) metabolites
dihydroxyoctamonoe- noic acids (DiHOMEs),
dihydroxyeicosatrienoic acids (DiHETrEs),
dihydroxyoctadecadienoic acids (DiHODEs),
dihydroxyeicosatetrae- noic acids (DiHETEs), and
dihydroxydocosapentaenoic acids (DiHDPEs). Each fatty acid
precursor and its oxylipin products are colored the same: LA,
orange; DGLA, yellow; ETA, dark blue; ALA, purple; EPA,
green; DHA, red; and ARA, light blue.
Reprinted with kind permission from Springer Science
+Business Media: Metabolomics, Serum oxylipin profiles in IgA
nephropathy patients reflect kidney functional alterations,
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Figure S2.  Score plot of lipidomic profiles calculated by
PCA. There was a pattern among the data separating pre (grey
circles) and post (black circles) lipidomic profiles.
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Figure S3.  Score plot of oxylipin profiles calculated by
PCA. There was a pattern among the data separating pre (grey
circles) and post (black circles) oxylipin profiles.
(DOCX)
Figure S4.  Score plot of lipoprotein profiles calculated by
PCA. There was a pattern among the data separating male
(grey circles) and female (black circles) lipoprotein profiles.
(DOCX)
Figure S5.  Score plot of oxylipin profiles in each
individual subject calculated by OPLS-DA. There was a
clear separation between pre (grey circles) and post (black
circles) profiles in all of the participants.
(DOCX)
Figure S6.  Bar graphs of each individual subject’s %
change in the following metabolites (subjects ordered by
direction and magnitude of response on x axis): A) the
arachidonic acid cyclooxygenase metabolite prostaglandin
F2α (PGF2α); B) the soluble epoxide hydrolase (sEH)
eicosapentaenoic acid (EPA, 20:5n3) metabolite 8,9-
dihydroxyeicosatrienoic acid (8,9-DiHETE); C) the sEH
docosahexaenoic acid (DHA, 22:6n3) metabolite 19,20-
dihydroxydocosapentaenoic acid (19,20-DiHDPE); and D)
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because they either had >33% missing variables or were
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(DOCX)
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post profile (high loading values) and pre profile (low
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separating subjects 202 and 220 from the rest of the
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decreased post intervention at α ≤ 0.005.
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DHA.
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Table S8.  Variables with joint variation according to
O2PLS-DA modeling (the higher loading value, the more
influential the variable).
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Table S9.  Variables among the oxylipins with unique
variation (and little or no correlation with EPA and DHA)
according to O2PLS-DA modeling (the lower the value, the
more influential).
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Table S10.  Results from standard lease squares linear
regressions for each variable adjusted for age, gender,
body weight, and BMI, with p-values ≤ 0.05.
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Table S11.  Gender differences in response to treatment.
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